Gärtner Roland, Gasnier Barbara C H, Dietrich Johannes W, Krebs Bjarne, Angstwurm Matthias W A
Department of Endocrinology, Medizinische Klinik Innenstadt, University of Munich, D-80336 Munich, Germany.
J Clin Endocrinol Metab. 2002 Apr;87(4):1687-91. doi: 10.1210/jcem.87.4.8421.
In areas with severe selenium deficiency there is a higher incidence of thyroiditis due to a decreased activity of selenium-dependent glutathione peroxidase activity within thyroid cells. Selenium-dependent enzymes also have several modifying effects on the immune system. Therefore, even mild selenium deficiency may contribute to the development and maintenance of autoimmune thyroid diseases. We performed a blinded, placebo-controlled, prospective study in female patients (n = 70; mean age, 47.5 +/- 0.7 yr) with autoimmune thyroiditis and thyroid peroxidase antibodies (TPOAb) and/or Tg antibodies (TgAb) above 350 IU/ml. The primary end point of the study was the change in TPOAb concentrations. Secondary end points were changes in TgAb, TSH, and free thyroid hormone levels as well as ultrasound pattern of the thyroid and quality of life estimation. Patients were randomized into 2 age- and antibody (TPOAb)-matched groups; 36 patients received 200 microg (2.53 micromol) sodium selenite/d, orally, for 3 months, and 34 patients received placebo. All patients were substituted with L-T(4) to maintain TSH within the normal range. TPOAb, TgAb, TSH, and free thyroid hormones were determined by commercial assays. The echogenicity of the thyroid was monitored with high resolution ultrasound. The mean TPOAb concentration decreased significantly to 63.6% (P = 0.013) in the selenium group vs. 88% (P = 0.95) in the placebo group. A subgroup analysis of those patients with TPOAb greater than 1200 IU/ml revealed a mean 40% reduction in the selenium-treated patients compared with a 10% increase in TPOAb in the placebo group. TgAb concentrations were lower in the placebo group at the beginning of the study and significantly further decreased (P = 0.018), but were unchanged in the selenium group. Nine patients in the selenium-treated group had completely normalized antibody concentrations, in contrast to two patients in the placebo group (by chi(2) test, P = 0.01). Ultrasound of the thyroid showed normalized echogenicity in these patients. The mean TSH, free T(4), and free T(3) levels were unchanged in both groups. We conclude that selenium substitution may improve the inflammatory activity in patients with autoimmune thyroiditis, especially in those with high activity. Whether this effect is specific for autoimmune thyroiditis or may also be effective in other endocrine autoimmune diseases has yet to be investigated.
在严重缺硒地区,由于甲状腺细胞内硒依赖性谷胱甘肽过氧化物酶活性降低,甲状腺炎的发病率较高。硒依赖性酶对免疫系统也有多种调节作用。因此,即使是轻度缺硒也可能有助于自身免疫性甲状腺疾病的发生和维持。我们对患有自身免疫性甲状腺炎且甲状腺过氧化物酶抗体(TPOAb)和/或甲状腺球蛋白抗体(TgAb)高于350 IU/ml的女性患者(n = 70;平均年龄,47.5 +/- 0.7岁)进行了一项双盲、安慰剂对照的前瞻性研究。该研究的主要终点是TPOAb浓度的变化。次要终点是TgAb、促甲状腺激素(TSH)和游离甲状腺激素水平的变化以及甲状腺的超声图像和生活质量评估。患者被随机分为2个年龄和抗体(TPOAb)匹配的组;36例患者口服200微克(2.53微摩尔)亚硒酸钠/天,持续3个月,34例患者接受安慰剂。所有患者均补充左旋甲状腺素(L-T4)以维持TSH在正常范围内。通过商业检测方法测定TPOAb、TgAb、TSH和游离甲状腺激素。用高分辨率超声监测甲状腺的回声。硒组中TPOAb的平均浓度显著下降至63.6%(P = 0.013),而安慰剂组为88%(P = 0.95)。对TPOAb大于1200 IU/ml的患者进行亚组分析发现,硒治疗组患者的TPOAb平均降低40%,而安慰剂组则升高10%。在研究开始时,安慰剂组的TgAb浓度较低,且显著进一步下降(P = 0.018),而硒组则无变化。硒治疗组有9例患者的抗体浓度完全恢复正常,而安慰剂组为2例(通过卡方检验,P = 0.01)。这些患者的甲状腺超声显示回声恢复正常。两组患者的平均TSH、游离T4和游离T3水平均无变化。我们得出结论,补充硒可能改善自身免疫性甲状腺炎患者的炎症活动,尤其是活动度高的患者。这种作用是否对自身免疫性甲状腺炎具有特异性,或者对其他内分泌自身免疫性疾病是否也有效,还有待研究。